Advertisement

Topics

Latest "Stoke Therapeutics, Inc." News Stories - Page: 20

11:46 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Stoke Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Stoke Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Stoke Therapeutics, Inc. for you to read. Along with our medical data and news we also list Stoke Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Stoke Therapeutics, Inc. Companies for you to search.

Showing "Stoke Therapeutics" News Articles 476–500 of 7,900+

Thursday 7th March 2019

Mavenclad Poised To Be Big Mover For Merck KGaA

The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide...   


Seelos Therapeutics stock doubles on license of potential Parkinson's candidate created at UCLA

Under the terms of the license, Seelos paid UCLA $100,000 upfront and will pay royalties on net sales

Shares of biopharma GTx rocket on merger with cancer-therapeutics specialist Oncternal Therapeutics

Shareholders of Oncternal will hold roughly 75% of the combined company's shares


Apogenix Announces Oral and Poster Presentations at Upcoming International Conferences

DGAP-News: Apogenix AG / Key word(s): Conference/Conference 07.03.2019 / 10:05 The issuer is solely responsible for the content of this announcement. Press Release Apogenix Announces Oral and Poster Presentations at Upcoming International Conferences Heidelberg, Germany, March 7, 2019 - Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, anno...

Fluorescent Biosensors as Tools for Drug Therapeutics

Researchers in the School of Pharmacy at the University of Nottingham have been using Dolomite Microfluidic’s chips to enhance their work on drug encapsulation and therapeutic delivery. Dr Veeren Chauhan, Research Fellow in the Advanced Materials and Healthcare Technologies (AMHT) group, working withDr Jonathan AylottandDr Amjad Selo, explained: “We have been using Dolomite chips since...

Spark Therapeutics: Elucidating The Roche Acquisition

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦@PureTechH⁩ $PRTC https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partne

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets. $20M upfront ⁦ @PureTechH⁩ $PRTC https://www.businesswire.com/news/home/20190306005880/en/Akili-Shionogi-Announce-Strategic-Partnership-Develop-Commercialize …

Funding round raises $135M for Beam Therapeutics

Beam Therapeutics raised $135 million from a Series B funding round that will support development of 10 programs underway uti -More- 

Beam Therapeutics secures $135m funds to expand pipeline of precision genetic medicines

Proceeds from the financing will be used to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific The post Beam Therapeutics secures $135m funds to expand pipeline of precision genetic medicines appeared first on Pharmaceutical Business review.

Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from ...

Well-Validated, Pre-Clinical Success Shown in the Reduction of Alpha-Synuclein New Compound Expands Seelos’ Parkinson's Portfolio NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) Read more...

Beam Therapeutics Closes Series B Financing Worth $135 Million http://dlvr.it/R0LXrV pic.twitter.com/yjEgPlk4SN

Beam Therapeutics Closes Series B Financing Worth $135 Million http://dlvr.it/R0LXrV  pic.twitter.com/yjEgPlk4SN

Executives On The Move: Bio/Med Changes Made From Lilly And Amgen, And A Step Up R&D Ladder At Daiichi Sankyo

Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen...  

OurCrowd Launches $50M Medtech Fund

Fund to focus on disruptive medical technologies and therapeutics with the potential to transform global healthcare delivery and patient outcomes OurCrowd, a leading global investment platform and Israel’s most active venture investor, announced today the launch of the OurCrowd Medtech Fund. The $50m fund will focus exclusively on investing in...

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets

Akili to Create First-of-its-kind International Digital Medicine Development and Commercial Platform Shionogi to Oversee Clinical Development, Sales and Marketing for ADHD and Autism Spectrum Disorder Digital Therapeutics in Japan and Taiwan Upfront and potential milestone payments for Japan and Taiwan commercialization valued up t...

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive ...

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) Read more...

Wednesday 6th March 2019

Beam Therapeutics raises $135m to advance CRISPR technologies

US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development...Read More... The post Beam Therapeutics raises $135m to advance CRISPR technologies appeared first on Pharmaceutical Technology.

Autolus Therapeutics to Host R&D Day on March 26, 2019

Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today ...

Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was a highly productive year for Ovid, with important milestones achieved in ...

Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA

Well-Validated, Pre-Clinical Success Shown in the Reduction of Alpha-Synuclein New Compound Expands Seelos’ Parkinson's Portfolio NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has acquired an exclusive license to intellectual property owned by The Regents of

Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019

DALLAS and FORT WORTH, Texas, March 07, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report its fourth quarter...

Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting

Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain;pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the mechanism of action; and efficacy,safety and pharmacokinetic profile from late-stage clinical trials BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focu...

Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2018 financial results and provide a corporate update on Thursday, March 14, 2019. Harpoon’s management will host a webcast and conference ...

INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results

PHOENIX, March 07, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its fourth quarter and full year ended Dec. 31, 2018. RECENT HIGHLIGHTS Advancing strategic alternatives review process for opioid-related assets to the nex...

Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

NEWTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today reported financial results for the quarter and full year ended December 31, 2018 and provided an update on the Company’...

Assertio Therapeutics Inc (ASRT) CEO Arthur Higgins on Q4 2018 Results - Earnings Call Transcript


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks